Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Makoto Ueno

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4480-0029; OpenAlex author ID A5050530209, A5101107767, A5110756969. Sources: OpenAlex.

Their work

Papers
119 (first author 19, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
326
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: 6 papers · 2016: 8 papers · 2017: 5 papers · 2018: 8 papers · 2019: 6 papers · 2020: 8 papers · 2021: 9 papers · 2022: 12 papers · 2023: 11 papers · 2024: 15 papers · 2025: 17 papers · 2026: 9 papers

Papers 50 of 119

  1. Plasma Protein Biomarkers for Early Detection of Pancreatic Cancer. Co-author DOI 10.1002/ijc.70637↗
  2. Circulating SDF4 as a potential diagnostic marker for early-stage pancreatic cancer Co-author DOI 10.1038/s41598-026-63925-x↗
  3. Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer. Co-author DOI 10.1056/nejmoa2600752↗
  4. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. Co-author DOI 10.1056/nejmoa2605555↗
  5. Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geria… Last author DOI 10.1093/jjco/hyag055↗
  6. Associations Between Obesity, Diabetes Mellitus, and Pancreatic Cancer in the Japanese Population: A Mendelian Randomization Study. Co-author DOI 10.1111/cas.70344↗
  7. Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II t… Last author DOI 10.1186/s12885-026-15699-8↗
  8. 6-mm versus 10-mm covered self-expandable metal stents and plastic stents for malignant distal biliary obstruction in resectable or borderline resectable pancr… Co-author DOI 10.1186/s13063-026-09821-1↗
  9. Tissue Factor as a Prognostic and Therapeutic Biomarker in Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-19380-z↗
  10. Electronic Patient-Reported Outcome Quality of Life Score in Japanese Patients With Pancreatic Cancer on Second-Line Chemotherapy: A Multicenter Observational … Co-author DOI 10.1002/cam4.71161↗
  11. Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of trea… Co-author DOI 10.1007/s00535-024-02186-9↗
  12. Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probabi… Co-author DOI 10.1007/s00535-025-02215-1↗
  13. Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment. Co-author DOI 10.1016/j.ejca.2025.115424↗
  14. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer. Co-author DOI 10.1016/j.esmoop.2025.105826↗
  15. Depth of response in patients with locally advanced pancreatic cancer treated with first-line chemotherapy: A supplementary analysis of JCOG1407. Last author DOI 10.1016/j.pan.2025.02.005↗
  16. Clinical importance of suspicious for malignancy compared to positive for malignancy in peritoneal cytology for surgically resected pancreatic cancer. Co-author DOI 10.1016/j.pan.2025.05.006↗
  17. Outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in patients with early recurrent pancreatic cancer after adjuvant S-1 treatment: A propensity sco… Co-author DOI 10.1016/j.pan.2025.08.017↗
  18. Serum laminin γ2 monomer as a novel diagnostic and prognostic marker for pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s44276-024-00116-z↗
  19. NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: an open-label, phase II trial design. Co-author DOI 10.1080/14796694.2025.2469467↗
  20. Impact of Statin Use on Survival in Patients With Unresectable Pancreatic cancer Receiving Gemcitabine Plus Nab-Paclitaxel: A Multicenter Retrospective Study. Co-author DOI 10.1097/mpa.0000000000002411↗
  21. Peritoneum carcinomatosis as a favourable prognostic factor for treatment with nanoliposomal irinotecan and fluorouracil plus leucovorin in advanced pancreatic… Co-author DOI 10.1177/17588359251351540↗
  22. Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 St… Co-author DOI 10.1200/jco-25-00746↗
  23. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  24. Overexpression of Nuclear Factor of Activated T-cells (NFAT) Transcription Factors Drives Chemoresistance and Poor Outcomes in Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18186-9↗
  25. A multicenter prospective study to determine the optimal range of lymph node dissection in pancreatic cancer surgery after neoadjuvant chemotherapy (LYMRIN-Tri… Co-author DOI 10.1371/journal.pone.0325667↗
  26. Significance of Preoperative Chemotherapy and Chemoradiotherapy in Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer. Co-author DOI 10.21873/anticanres.17804↗
  27. Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemoth… Co-author DOI 10.1002/jhbp.12066↗
  28. Clinical usefulness of C-reactive protein-albumin-lymphocyte (CALLY) index as a prognostic biomarker in patients undergoing surgical resection of pancreatic ca… Co-author DOI 10.1007/s00423-024-03512-8↗
  29. Liposomal irinotecan plus fluorouracil/leucovorin in older patients with advanced pancreatic cancer: a single-center retrospective study. Co-author DOI 10.1007/s10147-023-02432-9↗
  30. Early tumor shrinkage as a prognostic predictor in chemotherapy-naïve patients with locally advanced pancreatic cancer treated with modified FOLFIRINOX or gemc… Last author DOI 10.1016/j.pan.2024.07.006↗
  31. Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer. Co-author DOI 10.1038/s41416-024-02834-0↗
  32. A Phase 2 study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer. First author DOI 10.1038/s44276-023-00028-4↗
  33. Protocol digest of a randomized phase III trial comparing S-1-based chemoradiotherapy with/without nivolumab for unresectable locally advanced or borderline re… Last author DOI 10.1093/jjco/hyae084↗
  34. Evaluation of pancreatic cancer specimens for comprehensive genomic profiling. Co-author DOI 10.1111/pin.13416↗
  35. A multi-institutional randomized phase III study comparing minimally invasive distal pancreatectomy versus open distal pancreatectomy for pancreatic cancer; Ja… Last author DOI 10.1186/s12885-024-11957-9↗
  36. Prognostic nutritional index is an independent risk factor for continuing S-1 adjuvant chemotherapy in patients with pancreatic cancer who received neoadjuvant… Co-author DOI 10.1186/s12885-024-13244-z↗
  37. Clinical Impact of Preoperative Neutrophil-to-Lymphocyte Ratio in Surgical Patients With Pancreatic Cancer. Co-author DOI 10.21873/anticanres.16805↗
  38. Clinical Impact of Preoperative Prognostic Nutritional Index in Surgical Patients With Pancreatic Cancer Treated With Perioperative Adjuvant Chemotherapy. Co-author DOI 10.21873/anticanres.16970↗
  39. Loss of Skeletal Muscle Mass During Neoadjuvant Chemotherapy for Pancreatic Cancer Is Related to the Continuation of S-1 Adjuvant Chemotherapy After Pancreatec… Co-author DOI 10.21873/anticanres.17286↗
  40. Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors. Co-author DOI 10.2217/fon-2023-0963↗
  41. Quality-of-life survey of pancreatic cancer patients: a comparison between general public and physicians. Co-author DOI 10.3389/frhs.2024.1275496↗
  42. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  43. Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adapti… Co-author DOI 10.1016/j.eclinm.2023.101897↗
  44. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Co-author DOI 10.1016/j.ejca.2022.12.014↗
  45. Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer. Co-author DOI 10.1038/s41416-023-02189-y↗
  46. Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety… First author DOI 10.1093/jjco/hyac177↗
  47. Effect of systemic inflammatory response on induction chemotherapy followed by chemoradiotherapy for locally advanced pancreatic cancer: an exploratory subgrou… Co-author DOI 10.1093/jjco/hyad044↗
  48. [Cutting edge of chemotherapy for advanced pancreatic cancer]. First author DOI 10.11405/nisshoshi.120.629↗
  49. FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational… Co-author DOI 10.1186/s12885-023-10654-3↗
  50. Risk factors for early recurrence in patients with pancreatic ductal adenocarcinoma who underwent curative resection. Co-author DOI 10.1186/s12957-023-03141-3↗

Closest collaborators

The 25 strongest of 326 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Satoshi Kobayashi · 48 shared papers, 2014–2026 · strength 6.34
  2. Junji Furuse · 38 shared papers, 2012–2026 · strength 5.76
  3. Masafumi Ikeda · 30 shared papers, 2012–2026 · strength 3.92
  4. Soichiro Morinaga · 34 shared papers, 2014–2026 · strength 3.70
  5. Masaaki Murakawa · 31 shared papers, 2014–2026 · strength 3.62
  6. Masato Ozaka · 24 shared papers, 2014–2026 · strength 3.57
  7. Naoto Yamamoto · 22 shared papers, 2014–2025 · strength 3.01
  8. Manabu Morimoto · 34 shared papers, 2014–2024 · strength 2.96
  9. Takuji Okusaka · 21 shared papers, 2012–2026 · strength 2.60
  10. Chigusa Morizane · 16 shared papers, 2012–2025 · strength 2.29
  11. Naohiro Okano · 15 shared papers, 2020–2026 · strength 2.19
  12. Shinnosuke Kawahara · 11 shared papers, 2022–2026 · strength 1.95
  13. Hiroshi Ishii · 20 shared papers, 2011–2026 · strength 1.92
  14. Nobumasa Mizuno · 19 shared papers, 2016–2026 · strength 1.88
  15. Yuto Kamioka · 10 shared papers, 2020–2026 · strength 1.69
  16. Toru Aoyama · 21 shared papers, 2014–2025 · strength 1.62
  17. Tatsuya Ioka · 14 shared papers, 2016–2026 · strength 1.48
  18. Mariko Kamiya · 9 shared papers, 2018–2026 · strength 1.40
  19. Kumiko Umemoto · 10 shared papers, 2020–2025 · strength 1.38
  20. Takeshi Terashima · 9 shared papers, 2017–2025 · strength 1.37
  21. Shun Tezuka · 11 shared papers, 2016–2025 · strength 1.36
  22. Naoki Sasahira · 9 shared papers, 2018–2026 · strength 1.30
  23. Shin Maeda · 8 shared papers, 2018–2026 · strength 1.29
  24. Hiroshi Imaoka · 8 shared papers, 2020–2025 · strength 1.18
  25. Akihiro Ohba · 7 shared papers, 2021–2025 · strength 1.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.